Papers/PMID:15049985
Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
BJU international2004The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Serenoa repens — decreases nocturnal voiding frequency (nocturia)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Placebo was associated with a reduction in the mean number of nocturnal voids of 0.63 (0.14); there was a further reduction attributable to Permixon of 0.38 (0.07) (P < 0.001).”
Quoted verbatim from Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.. - Study
- meta-analysis
- Population
- Men with symptomatic BPH; pooled analysis of 14 randomized and 3 open-label Permixon trials (total N=4280) vs placebo
Effect 0.38 mean difference
Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.2004PMID:15049985Permalink